Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf (Lung-EPICLIN/G)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01562665
First received: February 22, 2012
Last updated: July 30, 2014
Last verified: July 2014

February 22, 2012
July 30, 2014
August 2012
December 2015   (final data collection date for primary outcome measure)
Use of health resources by collecting data about hospital description and characteristics, Disease Diagnosis Procedures and Therapy information [ Time Frame: April 2014(26 Months) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01562665 on ClinicalTrials.gov Archive Site
Patient-Reported Outcomes (PRO) through self-administered questionnaires and the patients will be asked to complete them at each evaluation visit(25% of the whole sample) [ Time Frame: April 2014(26 Months) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf
Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA

The overall aim of the study is:

To provide accurate and reliable information regarding NSCLC clinical management across MENA region in order to detect unmet medical needs of this disease in terms of:

  • Patient and hospital characteristics.
  • Diagnostic and treatment approaches: initial and subsequent.
  • Follow-up patterns in clinical management.
  • Outcomes: symptoms, death, functionality, quality of life.
  • Use of resources and burden on patients and health care systems.

Epidemiological study to describe NSCLC clinical management patterns in MENA

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Oncology Institutes

Non Small Cells Lung Cancer
Not Provided
  • All Population
  • Sample of patients will be invited to complete Quality of Life
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between November 1st, 2011 and August 30th, 2012 For PRO
  • Sub-sample:

    • ability to read and write since they will be asked to participate in the PRO part of the study.
  • Selection will not be based on the disease stage of each patient, in order to avoid a selection bias.

Exclusion Criteria:

  • According to the study design there will not be any exclusion criteria in order to provide a high validity and to obtain the most accurate real daily practice information.
Both
Not Provided
No
Contact: Mohamed Elsayed ClinicalTrialTransparency@astrazeneca.com
Bahrain,   Qatar,   United Arab Emirates
 
NCT01562665
NIS-OAE-XXX-2011/1
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Kakil Rasul, CONSULTANT Hamad Medical Corporation, Doha, Qatar
Principal Investigator: Ahmed El Khodary, CONSULTANT Kuwait Cancer Centre, Al Sabah Hospital, Kuwait
Principal Investigator: Norbert Drier, CONSULTANT Zayed Military Hospital, Abu Dhabi, United Arab Emirates
Principal Investigator: Farid Khalifa, CONSULTANT Salmaniya Medical Complex, Bahrain
Principal Investigator: Mohamed Jaloudy, CONSULTANT Tawam Hospital ,Alain,Abu Dhabi, United Arab Emirates
AstraZeneca
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP